https://www.selleckchem.com/products/t0070907.html
Ninety-three participants were randomised and 80 were included in the analysis, ages 18-69 years; HbA1c levels 5.4-10.6%; 66% female. Compared to SAP, E-N CLC reduced overall time 70mg/dL from 4.0% to 2.2% () resulting in an absolute difference of 1.8% (95%CI 1.2-2.4%), p0.0001. This was accompanied by overall reduction in HbA from 7.4% at baseline to 7.1% at the end of study, resulting in an absolute difference of 0.3% (95% CI 0.1-0.4%), p0.0001. There were 5 severe hypoglycaemia adverse events attributed to user-directed
पसंद करना
टिप्पणी
शेयर करना
